A carregar...
From randomized clinical trials to real life data. An Italian clinical experience with ixekizumab and its management.
Interleukin(IL)-17 inhibitors display higher efficacy than both TNFi and IL-12/23i, which increased the goal psoriasis area severity index (PASI) from 75 to PASI 90 or even PASI 100. Ixekizumab, a recombinant, humanized IgG4 monoclonal antibody targeting IL-17A displayed a high efficacy and safety i...
Na minha lista:
| Publicado no: | Dermatol Ther |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6579640/ https://ncbi.nlm.nih.gov/pubmed/30942952 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dth.12886 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|